Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

A novel immune checkpoint-based signature predicts immunotherapy benefit in "driver gene-negative" lung adenocarcinoma.

Cancer letters - 1 Oct 2026

Luo Baohong, Zhan Qinru, Chen Yu, Zhou Qian, Fu Tongze, Chen Xiang, He Qiong, Li Shuhua, Chen Zhe-Sheng, Ke Zunfu

Abstract excerpt

Immune checkpoint blockade (ICB) is regarded as a major breakthrough in lung cancer treatment. However, the limited response rates and immune-related adverse events associated with ICB present major challenges in clinical practice. To predict the immunotherapy response, we developed the CCCNP signature comprising 5 immune checkpoint molecules (CD226, CD276, CTLA-4, Nectin-2, and PD-L1) in "driver gene-negative"...

Topics

Humans
Lung Neoplasms
Adenocarcinoma of Lung
Female
Male
Immune Checkpoint Inhibitors
Biomarkers, Tumor
Immunotherapy
Middle Aged
Aged
Retrospective Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Prognosis

Mutation

Prospective Studies

Source

Identifiers

PMID: 42431392
DOI: 10.1016/j.canlet.2026.218726

Genes

CD226
CD276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel immune checkpoint-based signature predicts immunotherapy benefit in "driver gene-negative" lung adenocarcinoma.PMID 42431392Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.Semantic proximity Read ↗

Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors.Semantic proximity Read ↗

Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinomaSemantic proximity Read ↗

Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitorsSemantic proximity Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.Semantic proximity Read ↗

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung AdenocarcinomaSemantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.